143 related articles for article (PubMed ID: 34148055)
1. Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.
Pepper AGS; Zucchetto A; Norris K; Tissino E; Polesel J; Soe Z; Allsup D; Hockaday A; Ow PL; Hillmen P; Rawstron A; Catovsky D; Bulian P; Bomben R; Baird DM; Fegan CD; Gattei V; Pepper C
Leukemia; 2022 Jan; 36(1):271-274. PubMed ID: 34148055
[No Abstract] [Full Text] [Related]
2. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations.
Jain N; Thompson P; Burger J; Ferrajoli A; Takahashi K; Estrov Z; Borthakur G; Bose P; Kadia T; Pemmaraju N; Sasaki K; Konopleva M; Jabbour E; Garg N; Wang X; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang S; Lopez W; Ayala A; Plunkett W; Gandhi V; Kantarjian H; O'Brien S; Keating M; Wierda WG
Leukemia; 2021 Dec; 35(12):3421-3429. PubMed ID: 34007049
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments.
Visentin A; Facco M; Gurrieri C; Pagnin E; Martini V; Imbergamo S; Frezzato F; Trimarco V; Severin F; Raggi F; Scomazzon E; Pravato S; Piazza F; Semenzato G; Trentin L
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):678-685.e4. PubMed ID: 31371221
[TBL] [Abstract][Full Text] [Related]
5. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia.
Thompson PA; Tam CS; O'Brien SM; Wierda WG; Stingo F; Plunkett W; Smith SC; Kantarjian HM; Freireich EJ; Keating MJ
Blood; 2016 Jan; 127(3):303-9. PubMed ID: 26492934
[TBL] [Abstract][Full Text] [Related]
7. Telomere length predicts for outcome to FCR chemotherapy in CLL.
Norris K; Hillmen P; Rawstron A; Hills R; Baird DM; Fegan CD; Pepper C
Leukemia; 2019 Aug; 33(8):1953-1963. PubMed ID: 30700843
[TBL] [Abstract][Full Text] [Related]
8. FCR achieves long-term durable remissions in patients with
Chai-Adisaksopha C; Brown JR
Blood; 2017 Nov; 130(21):2278-2282. PubMed ID: 29025740
[TBL] [Abstract][Full Text] [Related]
9. The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
Jain P; Nogueras González GM; Kanagal-Shamanna R; Rozovski U; Sarwari N; Tam C; Wierda WG; Thompson PA; Jain N; Luthra R; Quesada A; Sanchez-Petitto G; Ferrajoli A; Burger J; Kantarjian H; Cortes J; O'Brien S; Keating MJ; Estrov Z
Br J Haematol; 2018 Jan; 180(1):33-40. PubMed ID: 29164608
[TBL] [Abstract][Full Text] [Related]
10. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.
Ljungström V; Cortese D; Young E; Pandzic T; Mansouri L; Plevova K; Ntoufa S; Baliakas P; Clifford R; Sutton LA; Blakemore SJ; Stavroyianni N; Agathangelidis A; Rossi D; Höglund M; Kotaskova J; Juliusson G; Belessi C; Chiorazzi N; Panagiotidis P; Langerak AW; Smedby KE; Oscier D; Gaidano G; Schuh A; Davi F; Pott C; Strefford JC; Trentin L; Pospisilova S; Ghia P; Stamatopoulos K; Sjöblom T; Rosenquist R
Blood; 2016 Feb; 127(8):1007-16. PubMed ID: 26675346
[TBL] [Abstract][Full Text] [Related]
11. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
Schlette EJ; Admirand J; Wierda W; Abruzzo L; Lin KI; O'Brien S; Lerner S; Keating MJ; Tam C
Leuk Lymphoma; 2009 Oct; 50(10):1597-605. PubMed ID: 19863337
[TBL] [Abstract][Full Text] [Related]
12. CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.
Majid A; Lin TT; Best G; Fishlock K; Hewamana S; Pratt G; Yallop D; Buggins AG; Wagner S; Kennedy BJ; Miall F; Hills R; Devereux S; Oscier DG; Dyer MJ; Fegan C; Pepper C
Leuk Res; 2011 Jun; 35(6):750-6. PubMed ID: 21093051
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive assessment of prognostic factors predicting outcome in Chinese patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide.
Xu M; Fan L; Miao KR; Liu P; Xu W; Li JY
Med Oncol; 2012 Sep; 29(3):2102-10. PubMed ID: 21881978
[TBL] [Abstract][Full Text] [Related]
14. 98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia.
Shi K; Sun Q; Qiao C; Zhu H; Wang L; Wu J; Wang L; Fu J; Young KH; Fan L; Xia Y; Xu W; Li J
Cancer Med; 2020 Feb; 9(3):999-1007. PubMed ID: 31849198
[TBL] [Abstract][Full Text] [Related]
15. Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption.
Delgado J; Salaverria I; Baumann T; Martínez-Trillos A; Lee E; Jiménez L; Navarro A; Royo C; Santacruz R; López C; Payer AR; Colado E; González M; Armengol L; Colomer D; Pinyol M; Villamor N; Aymerich M; Carrió A; Costa D; Clot G; Giné E; López-Guillermo A; Campo E; Beà S
Haematologica; 2014 Nov; 99(11):e231-4. PubMed ID: 24997154
[No Abstract] [Full Text] [Related]
16. Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.
Lanasa MC; Davis PH; Datto M; Li Z; Gockerman JP; Moore JO; DeCastro CM; Friedman DR; Diehl LF; Rehder C; Cook H; Daugherty FJ; Matta KM; Weinberg JB; Rizzieri D
Leuk Lymphoma; 2012 Feb; 53(2):218-24. PubMed ID: 21827374
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
[TBL] [Abstract][Full Text] [Related]
18. Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia.
Šimkovič M; Vodárek P; Motyčková M; Écsiová D; Rozsívalová P; Móciková H; Štěpánková P; Sýkorová A; Hrochová K; Vrbacký F; Belada D; Žák P; Smolej L
Eur J Clin Invest; 2021 Apr; 51(4):e13421. PubMed ID: 33022756
[TBL] [Abstract][Full Text] [Related]
19. A biclonal case of chronic lymphocytic leukaemia with discordant mutational status of the immunoglobulin heavy chain variable region and bimodal CD49d expression.
Hotinski AK; Best OG; Thurgood LA; Lower KM; Kuss BJ
Br J Haematol; 2021 Feb; 192(3):e77-e81. PubMed ID: 33278845
[No Abstract] [Full Text] [Related]
20. Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group.
Smolej L; Brychtová Y; Cmunt E; Doubek M; Špaček M; Belada D; Šimkovič M; Stejskal L; Zygulová I; Urbanová R; Brejcha M; Zuchnická J; Móciková H; Kozák T;
Br J Haematol; 2021 May; 193(4):769-778. PubMed ID: 33618437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
